Brain and Central Nervous System Tumors
Conditions
Keywords
childhood infratentorial ependymoma, childhood supratentorial ependymoma, newly diagnosed childhood ependymoma
Brief summary
RATIONALE: Drugs used in chemotherapy, such as methotrexate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well high-dose methotrexate works in treating young patients with residual ependymoma.
Detailed description
OBJECTIVES: Primary * Determine the activity of high-dose methotrexate as upfront-window therapy in young patients with residual ependymoma. Secondary * Assess the reasons why primary surgery was complete/incomplete in these patients. * Assess the feasibility and toxicity of second-look surgery after 3 courses of high-dose methotrexate in cases where initial surgery was incomplete. OUTLINE: This is a multicenter, open-label study. Patients receive high-dose methotrexate IV continuously over 24 hours on days 0, 14, and 28 in the absence of disease progression or unacceptable toxicity. Patients then proceed to further chemotherapy on protocol UKCCSG-CNS-9204. After completion of study treatment, patients are followed periodically for 9 years. PROJECTED ACCRUAL: A total of 29 patients will be accrued for this study.
Interventions
DRUGmethotrexate
PROCEDUREadjuvant therapy
Sponsors
Children's Cancer and Leukaemia Group
Study design
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 2 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed ependymoma, including the following histologic variants: * Cellular * Papillary * Clear-cell * Tanycytic * Anaplastic (malignant) ependymoma * The following diagnoses are excluded: * Myxopapillary ependymoma * Subependymomas * Ependymoblastomas * Primitive neuroectodermal tumors (PNETs) * Other neuroepithelial tumors * Choroid plexus tumors * Germ cell tumors * Residual measurable ependymoma after maximal surgical resection, including second-look surgery, if deemed necessary * Has undergone surgical resection within the past 3 weeks PATIENT CHARACTERISTICS: * At least 3 months to under 3 years of age * Neutrophil count \> 1,000/mm\^3 * Platelet count \> 100,000/mm\^3 * Able to tolerate chemotherapy * No co-existent unrelated disease (i.e., renal or hematological) that would preclude chemotherapy treatment PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Recovered from prior surgery * No previous chemotherapy * Previous steroids allowed * No previous radiotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Activity of high-dose methotrexate at 6 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Assess reasons why primary surgery is complete or incomplete at diagnosis | — |
| Feasibility and toxicity of second look surgery after course 3 at 2 months | — |
| Compare functional imaging studies of ependymomas with biological characteristics of the tumors at diagnosis | — |
Countries
Ireland, United Kingdom
Outcome results
None listed